Strota/ Newsroom/ 2026-06-22

SUNPHARMA gained +1.4% on a box breakout

Strota Newsroom · session of 2026-06-22 · market close · SUNPHARMA stock page →

Sun Pharmaceutical Industries Ltd. (SUNPHARMA) gained +1.4% to ₹1,863.50 with 1 signal firing. Here is what the exchange data shows.

Sun Pharmaceutical Industries Ltd. closed at ₹1,863.50 on Monday, up 1.37 per cent from its previous close of ₹1,838.30, outperforming the Nifty which gained 0.37 per cent. The stock opened marginally lower with a gap of -0.18 per cent, then traded in a range between ₹1,834.50 and ₹1,864.40 before finishing near the day's high. The session marked a recovery from the weakness seen in mid-June, when the stock had dropped for five straight sessions according to a headline from Business Standard dated 18 days ago.

The technical picture shows the stock in a constructive position. The 14-day RSI stands at 64.9, below overbought territory but indicating positive momentum. Sun Pharma is trading above both its 50-day and 200-day moving averages, though it has not triggered a golden cross formation. A Darvas breakout signal is active, suggesting the stock has moved above its recent consolidation box. The counter is just 2.8 per cent below its 52-week high and has advanced 20.34 per cent from its 52-week low. Over the past week, the stock has returned 3.15 per cent, while the one-month gain is a modest 0.99 per cent. Relative volume at 0.61 indicates participation was below average compared to the 20-day pattern.

The news flow centres on a planned acquisition. According to a headline from Pharmaceutical Technology published six hours ago, Sun Pharma is set to acquire Innovcare Lifesciences for $28.7 million. A similar headline from scanx.trade a day earlier put the deal value at ₹271.2 crore, while NDTV Profit reported two days ago that the company would acquire 100 per cent of Invocare Lifesciences for approximately ₹271 crore — suggesting the same transaction with slight variations in naming. This follows a broader pattern of Indian pharmaceutical companies expanding abroad, as noted in a BBC headline from 29 days ago that mentioned Sun Pharma among businesses shopping overseas as domestic growth slows.

The recent earnings backdrop is mixed. Reuters headlines from 31 days ago indicated Sun Pharma beat profit expectations on strong demand for specialty drugs, though one report noted shares slid on cost pressures. There are no fresh institutional deal disclosures in the past 30 days, no streak of consecutive buying or selling by large funds, and no insider filings in the last 60 days. Futures and options positioning data was not available in the evidence pack.

On the charts, the immediate watch zone sits at the day's high of ₹1,864.40, where the stock closed. A sustained move above this level would signal upside continuation, while a drop back below the previous close of ₹1,838.30 would flip the near-term bias bearish. The stock has already cleared this hurdle once; whether it holds will determine the next leg.

What the data establishes is a modest gain on below-average volume, supported by acquisition headlines and a technically sound setup, but without fresh institutional conviction or options market positioning to confirm broader participation. What it does not establish is whether the acquisition news alone drove today's move, or whether the stock was simply recovering from its recent five-session decline in line with the broader market. The evidence shows no single obvious catalyst beyond the confluence of deal news and technical repair.

The numbers

Signals that fired

Technical context

Volume ran at 0.6× its 20-day average; rsi(14) sits at 65; price is 2.8% from the 52-week high; trading above the 50-dma and 200-dma.

Recent headlines

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.